In summary, our comparative transcriptomics analysis demonstrated that Trem2 signaling drove the formation of a robust anti-inflammatory microglial subgroup, the NEUD-MDL (Trem2-DAM), within the context of AD amyloid pathology. This evidence concerns the gene TREM2 and Alzheimer disease.